 99MTC(III) myocardial imaging agents and method of use |
| OF THE INVENTION The technetium compounds of the present invention which have been found most ... |
|
| 1,4-dihydro-4-oxo-3-quinoline derivatives as selectively toxic mammalian antibacterial agents |
| OF THE INVENTION Compounds of the formula I may be prepared as illustrated in the following ... |
|
| Vaginal sponge delivery system |
| These and other objects of the invention are achieved in a product which broadly comprises (a) a ... |
|
| Controlled release formulation |
| What is claimed is: 1. In a controlled release angiotensin converting enzyme inhibitor formulation ... |
|
| Formulations providing three distinct releases |
| We claim: 1. A therapeutic composition for oral administration consisting essentially of a ... |
|
| Floating sustained release therapeutic compositions |
| OF THE INVENTION According to the present invention, therapeutic dosage forms have now been ... |
|
| Solid oral dosage forms of ifosfamide |
| OF PREFERRED EMBODIMENTS The invention is illustrated by the following examples: EXAMPLE 1 I... |
|
| [(benzodioxan, benzofuran or benzopyran) alkylamino] alkyl substituted guanidines |
| We claim: 1. A compound of the formula: ##STR259## a pharmaceutically acceptable acid addition salt ... |
|
| Methods for treating dermatitis using descarboethoxyloratadine |
| OF THE INVENTION The present invention encompasses a method of treating allergic asthma in a human ... |
|
| Fat emulsions containing isocarbacyclin |
| What is claimed is: 1. A pharmaceutical prostaglandin emulsion comprising: a mixture of vegetable ... |
|
|
Corneal angiogenesis inhibitor
| Details |
Inventors: Sone, Saburo; Kajita, Akemi; Satoh, Yu-ichiro;
Assignee: Toray Industries, Inc. (Tokyo, JP)
Primary Examiner: Feisee; Lila
Assistant Examiner: Bansal; Geetha P.
Attorney, Agent or Firm: Birch, Stewart, Kolasch & Birch, LLP
The present invention relates to a corneal angiogenesis inhibitor which has interferon .beta. as an active ingredient and which is used for preventing and treating neovascularization or invasion of vessels in the cornea. |
|
DETAILED DESCRIPTION What is claimed is: 1.
A method for treating corneal neovasculariztion which comprises: administering an effective amount of interferon .
beta.
for treating corneal neovascularization by inhibiting the proliferation of vascular endothelial cells, to a patient with corneal neovascularization.
2.
A method for inhibiting angiogenesis which comprises administering an effective amount of interferon .
beta.
for treating corneal neovascularization by inhibiting the proliferation of vascular endothelial cells, to a patient in need thereof.
3.
A method for treating corneal neovascularization according to claim 1, wherein said patient has a condition selected from the group consisting of Stevens-Johnson syndrome, ocular pemphigoid, corneal chemical injuries caused by cytotoxic agents, trachoma, viral infections, phlyctenular keratitis, keratoplasty, and injuries caused by wearing contact lenses for long periods of time.
Description:
TECHNICAL FIELD The present invention relates to a corneal angiogenesis inhibitor and also relates to a corneal angiogenesis inhibitor which is useful as a preventive or therapeutic agent to various kinds of diseases caused by abnormal vascular proliferation in the cornea.
BACKGROUND ART Neovascularization is deeply involved in the onset and progress of various kinds of inflammatory diseases such as rheumatoid arthritis and psoriasis; ocular diseases such as diabetic retinopathy, retinopathy of prematurity, senile macular degeneration, retinal vein occlusion, retrolental fibroplasia, neovascularization associated with keratoplasty, glaucoma, and ocular tumors; and various kinds of tumors.
In particular, it is known that neovascularization or invasion of vessels is observed in the corneas of patients with Stevens-Johnson syndrome and similar diseases; ocular pemphigoid and similar diseases; corneal chemical injuries caused by various kinds of agents having cytotoxicity, for example, alkaline, acid, detergents, various kinds of solvents, and volatile gases; trachoma; viral infections; phlyctenular keratitis; keratoplasty; and patients who use contact lenses for long periods
|
|
Vasodialators 
